Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck’s Zostavax Shingles Vaccine Approved

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approved the herpes zoster vaccine for patients ages 60 years and older.

You may also be interested in...



Merck’s Gardasil HPV Vaccine Clears FDA

The vaccine, which is administered in a three-dose series, is available for ordering at $120 per dose, Merck says.

Merck’s Gardasil HPV Vaccine Clears FDA

The vaccine, which is administered in a three-dose series, is available for ordering at $120 per dose, Merck says.

Merck Zostavax Shingles Vaccine Safe and Effective For Adults Over 60, Committee Says

FDA's Vaccines & Related Biological Products Advisory Committee said data do not support Merck's proposed indication for adults as young as 50 years.

Related Content

Topics

UsernamePublicRestriction

Register

PS064232

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel